NEW YORK (GenomeWeb) – Sialix said this week that it has raised an additional $2 million as part of its Series B round, bringing the total raised to $6 million.
The company also said that it has changed its name to Siamab Therapeutics, marking its shift from a glycomics-focused firm to one focused on developing therapeutic antibodies for cancer.
A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.
Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.
*Before your trial expires, we’ll put together a custom quote with your long-term premium options.
